Amgen Toekomstige groei

Future criteriumcontroles 3/6

Amgen zal naar verwachting groeien in winst en omzet met respectievelijk 19.8% en 2.3% per jaar. De winst per aandeel zal naar verwachting groeien met 19.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 365.3% zijn.

Belangrijke informatie

19.8%

Groei van de winst

19.9%

Groei van de winst per aandeel

Biotechs winstgroei	28.0%
Inkomstengroei	2.3%
Toekomstig rendement op eigen vermogen	365.3%
Dekking van analisten	Good
Laatst bijgewerkt	05 Nov 2024

Recente toekomstige groei-updates

Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Nov 02

Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next

Aug 09

Recent updates

Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market

Nov 03

Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Nov 02

Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable

Feb 08

Amgen: Accelerating The Business And Dividend Growth

Jan 29

Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?

Jan 29

Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks

Jan 22

Is Amgen (NASDAQ:AMGN) A Risky Investment?

Dec 28

Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors

Dec 13

Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?

Oct 23

Is Amgen (NASDAQ:AMGN) Using Too Much Debt?

Sep 22

Do Amgen's (NASDAQ:AMGN) Earnings Warrant Your Attention?

Sep 04

Winst- en omzetgroeiprognoses

NasdaqGS:AMGN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	34,884	7,505	13,124	13,527	23
12/31/2025	34,262	6,473	12,483	13,170	27
12/31/2024	33,204	4,272	12,189	13,794	24
9/30/2024	32,534	4,230	6,283	7,257	N/A
6/30/2024	30,934	3,130	5,481	6,446	N/A
3/31/2024	29,532	3,763	7,098	8,096	N/A
12/31/2023	28,190	6,717	7,359	8,471	N/A
9/30/2023	26,833	7,566	9,379	10,582	N/A
6/30/2023	26,582	7,979	9,685	10,800	N/A
3/31/2023	26,190	7,917	7,531	8,621	N/A
12/31/2022	26,323	6,552	8,785	9,721	N/A
9/30/2022	26,330	6,835	8,997	9,880	N/A
6/30/2022	26,384	6,576	8,355	9,320	N/A
3/31/2022	26,316	5,723	8,417	9,321	N/A
12/31/2021	25,979	5,893	8,381	9,261	N/A
9/30/2021	25,767	5,609	7,840	8,606	N/A
6/30/2021	25,484	5,746	8,897	9,556	N/A
3/31/2021	25,164	7,085	9,835	10,467	N/A
12/31/2020	25,424	7,264	9,889	10,497	N/A
9/30/2020	24,987	7,352	10,235	10,858	N/A
6/30/2020	24,301	7,299	10,209	10,867	N/A
3/31/2020	23,966	7,675	8,795	9,439	N/A
12/31/2019	23,362	7,842	8,532	9,150	N/A
9/30/2019	23,395	8,067	9,175	9,830	N/A
6/30/2019	23,562	7,958	9,070	9,726	N/A
3/31/2019	23,750	8,075	9,715	10,414	N/A
12/31/2018	23,747	8,394	10,558	11,296	N/A
9/30/2018	23,319	2,202	10,448	11,114	N/A
6/30/2018	23,188	2,364	N/A	11,295	N/A
3/31/2018	22,939	2,219	N/A	11,519	N/A
12/31/2017	22,849	1,979	N/A	11,177	N/A
9/30/2017	23,012	8,178	N/A	11,265	N/A
6/30/2017	23,050	8,174	N/A	10,473	N/A
3/31/2017	22,928	7,893	N/A	10,824	N/A
12/31/2016	22,991	7,722	N/A	10,354	N/A
9/30/2016	22,562	7,587	N/A	9,327	N/A
6/30/2016	22,474	7,433	N/A	9,557	N/A
3/31/2016	22,156	7,216	N/A	10,164	N/A
12/31/2015	21,662	6,939	N/A	9,731	N/A
9/30/2015	21,457	6,433	N/A	10,103	N/A
6/30/2015	20,765	5,814	N/A	9,952	N/A
3/31/2015	20,575	5,708	N/A	8,895	N/A
12/31/2014	20,063	5,158	N/A	8,952	N/A
9/30/2014	19,743	4,885	N/A	7,945	N/A
6/30/2014	19,460	5,009	N/A	7,011	N/A
3/31/2014	18,959	4,720	N/A	6,384	N/A
12/31/2013	18,676	5,081	N/A	6,291	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei AMGN ( 19.8% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van AMGN ( 19.8% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.4% per jaar).

Hoge groeiwinsten: De winst van AMGN zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van AMGN ( 2.3% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van AMGN ( 2.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen AMGN zal naar verwachting over 3 jaar zeer hoog zijn ( 365.3 %).

Amgen Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates increase by 25%

Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Amgen Inc. Provides Earnings Guidance for the Full Year 2024

Consensus EPS estimates fall by 19%

Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Recent updates

Consensus EPS estimates increase by 25%

Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market

Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Amgen Inc. Provides Earnings Guidance for the Full Year 2024

Third quarter 2024 earnings: EPS exceeds analyst expectations

Second quarter dividend of US$2.25 announced

Amgen Inc. Announces Dividend for the Fourth Quarter of 2024, Payable on December 9, 2024

Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List

Amgen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Amgen Announces Presents Positive Top-Line Results from the Phase 3 MINT Trial Evaluating the Efficacy and Safety of UPLIZNA

Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms

Amgen Inc. Appoints Anumita Tripathi as Director of Corporate Affairs for Amgen India

Amgen: Growth Is Still A Better Choice

Amgen Announces Otezla®? (Apremilast) Now Available in the U.S. for Moderate to Severe Plaque Psoriasis

Consensus EPS estimates fall by 19%

Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: EPS misses analyst expectations

Amgen: Shows Why Dividend Investing Is Getting Tougher

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q2, 2024 Results on Aug 06, 2024

Insufficient new directors

Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt

The Price Is Right For Amgen Inc. (NASDAQ:AMGN)

Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum

Amgen: You Haven't Seen Anything Yet

Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto

Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd)

Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card

Amgen Stock: Poised To Break Out (Technical Analysis)

New minor risk - Earnings quality

FDA Approves Amgen's IMDELLTRA™? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer

Insider recently sold US$663k worth of stock

Upcoming dividend of US$2.25 per share

Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?

New minor risk - Profit margin trend

First quarter 2024 earnings: EPS misses analyst expectations

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet

Amgen Inc. to Report Q1, 2024 Results on May 02, 2024

Amgen to Submits Marketing Authorization Application to the European Medicines Agency

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen: The Giant With An Impressive Pipeline

Is Amgen (NASDAQ:AMGN) Using Too Much Debt?

Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock

Amgen Will Benefit From Increased Medical Spending

Dividend of US$2.25 announced

Amgen Presents New Research on Otezla (Apremilast) at AAD 2024

Amgen Announces 2024 Second Quarter Dividend, Payable on June 7,2024

Amgen: A Good Dividend Growth Stock For The Watch List

Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit

Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now

Consensus EPS estimates fall by 20%

Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable

New minor risk - Earnings quality

Upcoming dividend of US$2.25 per share at 3.0% yield

Full year 2023 earnings: EPS misses analyst expectations

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q4, 2023 Results on Feb 06, 2024

Amgen: Accelerating The Business And Dividend Growth

Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?

Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks

Is Amgen (NASDAQ:AMGN) A Risky Investment?

Amgen Provides Regulatory Update on Status of LUMAKRAS (Sotorasib)

Amgen Inc. Announces Executive Changes

Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors

Executive VP recently sold US$2.7m worth of stock

Executive VP notifies of intention to sell stock

Upcoming dividend of US$2.13 per share at 3.1% yield

Amgen Presents New Data from Phase 2 Trial of Dazodalibep in Sjogren's Syndrome at ACR 2023